Atrium Therapeutics Inc (RNA)

SG&A Expense Growth

-50.58%

Quarterly · Period ending:

RNA logo

RNA SG&A Expense Growth

Latest reported-50.58%
RNA Quarterly SG&A Growth (QoQ) (0.00% → -50.58%)
High-resolution chart · PNG

RNA sg&a expense growth history

Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.

Atrium Therapeutics Inc SG&A Expense Growth — Quarterly
Period endingSG&A Expense Growth
-50.5844%
-33.852%
0%
0%
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.